RedHill Biopharma Shares Jump After Data Publication From COVID-19 Study

  • RedHill Biopharma Ltd RDHL announced the publication of positive data from a Phase 2 study RHB-107 (upamostat) in non-hospitalized symptomatic COVID-19 patients in the peer-reviewed International Journal of Infectious Diseases.
  • The study showed that RHB-107 met the primary endpoint of safety and tolerability and delivered promising efficacy results, despite the small number of patients in each treatment group, including faster recovery from severe COVID-19 symptoms and a 100% reduction in hospitalization due to COVID-19.
  • Related: RedHill Biopharma Says Its Oral Broad-Acting Antivirals Inhibit Dominant Omicron Sub-Variant BA.5.
  • Data showed a 100% reduction in hospitalization due to COVID-19, with zero patients (0/41) on the RHB-107 arms versus 15% (3/20) hospitalized on the placebo-controlled arm.
  • The study also showed an approximate 88% reduction in reported new severe COVID-19 symptoms after treatment initiation, with only 2.4% of the RHB-107 treated group (1/41) versus 20% (4/20) of patients in the placebo-controlled arm reporting new severe COVID-19 symptoms. 
  • Further analysis showed faster recovery from severe COVID-19 symptoms with a median of 3 days to recovery with upamostat vs. eight days with placebo.
  • Price Action: RDHL shares are up 27.2% at $0.18 on the last check Tuesday.
Loading...
Loading...
RDHL Logo
RDHLRedhill Biopharma Ltd
$1.801.88%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
2.38
Growth
14.45
Quality
Not Available
Value
44.59
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...